Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 8, 2012, Pages 833-843

  Bertera, Facundo Martín ^a   Mauro, Julieta Sofía Del ^a   Polizio, Ariel Héctor ^a   Chiappetta, Diego ^a   Taira, Carlos Alberto ^a   Höcht, Christian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Blood pressure; Blood pressure variability; Nebivolol; Pharmacokinetics; Spontaneously hypertensive rats; Sympathetic vascular activity

Indexed keywords

NEBIVOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; ENANTIOMER; ESSENTIAL HYPERTENSION; HEART BEAT; HEART RATE; MALE; NONHUMAN; RAT; SPECTROSCOPY; TREATMENT OUTCOME; WISTAR KYOTO RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BENZOPYRANS; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; ETHANOLAMINES; HEART RATE; HYPERTENSION; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; STEREOISOMERISM;

EID: 84864435119     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0756-9     Document Type: Article

References (42)

1. Aimone LD (2005) Overview of pharmacokinetics. Curr Protoc Pharmacol 7(1):1-26
2. Bertera F, Di Verniero CA, Mayer MA, Chiappetta D, Buontempo F, Polizio AH, Taira CA, Höcht C (2012a) Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats. Xenobiotica 42:206-219
3. Bertera FM, Del Mauro JS, Chiappetta D, Polizio AH, Buontempo F, Taira CA, Höcht C (2012b) Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats : Focus on blood pressure variability. Naunyn Schmiedebergs Arch Pharmacol 385:325-335
4. Chiladakis JA, Georgiopoulou E, Alexopoulos D (2004) Autonomic effects of nebivolol versus atenolol in healthy subjects. Cardiovasc Drugs Ther 18:469-473 (Pubitemid 40487025)
5. Cockcroft JR, Pedersen ME (2012) β-Blockade : Benefits beyond blood pressure reduction? J Clin Hypertens 14:112-120
6. Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC (2008) Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 104:1683-1689
7. Friberg P, Karlsson B, Nordlander M (1998) Sympathetic and parasympathetic influence on blood pressure and heart rate variability inWistar-Kyoto and spontaneously hypertensive rats. J Hypertens Suppl 6:S58-S60
8. Gao Y, Vanhoutte PM (2012) Nebivolol : An endothelium-friendly selective β1-adrenoceptor blocker. J Cardiovasc Pharmacol 59:16-21
9. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
10. Guerrero E, Voces F, Ardanaz N, Montero MJ, Arévalo M, Sevilla MA (2003) Long-term treatment with nebivolol improves arterial reactivity and reduces ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 42:48-55
11. Guerrero EI, Ardanaz N, Sevilla MA, Arévalo MA, Montero MJ (2006) Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. J Hypertens 24:151-158 (Pubitemid 41818100)
12. Höcht C, Di Verniero C, Opezzo JA, Bramuglia GF, Taira CA (2006) Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats : A microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 373:310-318 (Pubitemid 43999782)
13. Höcht C, Bertera FM, Mayer MA, Taira CA (2010a) Issues in drug metabolism of major antihypertensive drugs : Beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol 6:199-211
14. Höcht C, Bertera FM, Taira CA (2010b) Importance of blood pressure variability in the assessment of cardiovascular risk and benefits of antihypertensive therapy. Expert Rev Clin Pharmacol 3:617-621
15. Isanta JR, Lasheras B, Fos D, Cenarruzabeitia E (1987) Comparative diltiazem plasma clearance in normotensive and hypertensive rats. J Pharm Sci 76:862-865 (Pubitemid 18006831)
16. Janssen BJ, Tyssen CM, Struyker-Boudier HA (1991) Modification of circadian blood pressure and heart rate variability by five different antihypertensive agents in spontaneously hypertensive rats. J Cardiovasc Pharmacol 17:494-503
17. Janssen BJ, Oosting J, Slaaf DW, Persson PB, Struijker-Boudier HA (1995) Hemodynamic basis of oscillations in systemic arterial pressure in conscious rats. Am J Physiol 269:H62-H71
18. Kuroedov A, Cosentino F, Lüscher TF (2004) Pharmacologicalmechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 22:155-168 (Pubitemid 39391186)
19. Langager AM, Hammerberg BE, Rotella DL, Stauss HM (2007) Very low-frequency blood pressure variability depends on voltage-gated L-type Ca2+ channels in conscious rats. Am J Physiol Heart Circ Physiol 292:H1321-H1327 (Pubitemid 46377119)
20. Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y (2007) The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 63:575-582 (Pubitemid 46632567)
21. Mancia G, Grassi G (2000) Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol 35(Suppl 4): S15-S19
22. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T (2006) Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals : Role of antioxidant activity. J Cardiovasc Pharmacol 48:862-869 (Pubitemid 44276465)
23. Mason RP, Giles TD, Sowers JR (2009) Evolving mechanisms of action of beta blockers : Focus on nebivolol. J Cardiovasc Pharmacol 54:123-128
24. Meier K, Gorbey S, Lemmer B (2004) Effects of nebivolol and metoprolol on nitric oxide urinary excretion, on expression of eNOS and on blood pressure in SH-rats. Naunyn Schmiedebergs Arch Pharmacol 369(Suppl 1):R42
25. Miao CY, Xie HH, Zhan LS, Su DF (2006) Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens 24:1125-1135
26. Parati G (2005) Blood pressure variability : Its measurement and significance in hypertension. J Hypertens 23(Suppl 1):S19-S25
27. PintérováM, Kuneš J, Zicha J (2011) Altered neural and vascular mechanisms in hypertension. Physiol Res 60:381-402
28. Pladys P, Lahaie I, Cambonie G, Thibault G, Lê NL, Abran D, Nuyt AM (2004) Role of brain and peripheral angiotensin II in hypertension and altered arterial baroreflex programmed during fetal life in rat. Pediatr Res 55:1042-1049 (Pubitemid 38661798)
29. Rothwell PM (2011) Does blood pressure variability modulate cardiovascular risk? Curr Hypertens Rep 13:177-186
30. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS, ASCOT-BPLA and MRC Trial Investigators (2010) Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9:469-480
31. Sacco G, Evangelista S, Criscuoli M, Goso C, Bigioni M, Binaschi M, Manzini S, Maggi CA (2005) Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats. Eur J Pharmacol 511:167-174 (Pubitemid 40417723)
32. Schillaci G, Pucci G, Parati G (2011) Blood pressure variability : An additional target for antihypertensive treatment? Hypertension 58:133-135
33. Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT, Malan L (2011) Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans : The SABPA Study. Hypertens Res 34:1127-1134
34. Souza HC, Martins-Pinge MC, Dias da Silva VJ, Borghi-Silva A, Gastaldi AC, Blanco JH, Tezini GC (2008) Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton Neurosci 139:38-45
35. Stauss HM (2007) Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 34:362-388
36. Su DF, Miao CY (2001) Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 28:709-715
37. Terao N, Shen DD (1983) Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 227:369-375 (Pubitemid 14241128)
38. Tomlinson B, Dalal JJ, Huang J, Low LP, Park CG, Rahman AR, Reyes EB, Soenarta AA, Heagerty A, Follath F (2011) The role of β-blockers in the management of hypertension : An Asian perspective. Curr Med Res Opin 27:1021-1033
39. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PA (1988) Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 11:552-563
40. Webb AJ, Fischer U, Rothwell PM (2011) Effects of β-blocker selectivity on blood pressure variability and stroke : A systematic review. Neurology 77:731-737
41. Xie HH, Shen FM, Cao YB, Li HL, Su DF (2005) Effects of low-dose ketanserin on blood pressure variability, baroreflex sensitivity and end-organ damage in spontaneously hypertensive rats. Clin Sci (Lond) 108:547-552
42. Xie HH, Shen FM, Zhang XF, Jiang YY, Su DF (2006) Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs. Eur J Pharmacol 543:77-82